BENLYSTA in my practice

Dr. Alvin Wells, Rheumatologist

Paid consultant to GSK at the time of filming.

video transcript

DR WELLS: Hi, I’m Doctor Alvin Wells, a board-certified rheumatologist practicing in Franklin, Wisconsin.

ON-SCREEN TEXT: Dr. Alvin Wells, Rheumatologist
Paid consultant to GSK at the time of filming.

ON-SCREEN TEXT: “Let’s talk BENLYSTA”
Stay tuned for Important Product Information

DR WELLS: I have a busy rheumatology practice, I see over 300 patients a month, and some of those patients have lupus and when they come into my practice, they have significant disease activity. And what does that look like? Most rheumatologists who see lupus will know, they have the mucocutaneous symptoms, the tender and swollen joints, they have the rash, they have the ulcers.

ON-SCREEN TEXT: 
• Mucocutaneous symptoms
• Tender and swollen joints
• Rash
• Ulcers

DR WELLS: 
And when I think about the patients I have started BENLYSTA on, over the last several years, it has been the whole gamut of patients. I have an 18-year-old lady who just finished high school and going off to college, I have a young mother who has several kids, but I also have older patients in their 40s and 50s. And all of those patients despite their background therapy, what I call standard of care, they still have disease activity and that’s why I have been using BENLYSTA in those patients.

ON-SCREEN TEXT: 
“That’s why I have been using BENLYSTA”

DR WELLS: As an immunologist, I know how the drug works, the mechanism of action, ...

ON-SCREEN TEXT:
“I know how the drugs works”

DR WELLS: 
...I know the impact that it has on the signs and symptoms and that’s when I am really demanding, when I think about treating patients who have lupus.

ON-SCREEN TEXT: “I know the impact”

DR WELLS: So, as I follow these patients over years, you know, month to month, I am looking for improvement in all of the disease activities. The addition of BENLYSTA has made a very very useful component in my armamentarium in treating patients with lupus disease activity.

ON-SCREEN TEXT: BENLYSTA: a very useful component in my armamentarium

ON-SCREEN TEXT: BENLYSTAHCP.com

DR WELLS: Thank you for watching. Visit the BENLYSTA website for more information.

ON-SCREEN BUTTON: Visit the website

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies. |
©2022 GSK or licensor. BELVID220050 August 2022. Produced in USA.

You may also like

Why BENLYSTA?

Dr. Alvin Wells, Rheumatologist

BENLYSTA patient story

Dr. Alvin Wells, Rheumatologist

Paid consultants to GSK at the time of filming.

Icon: Computer

Join us for a live webinar

Learn more